Trial · NCT07884058
IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
NCT07884058, Phase 2, Not yet recruiting, University of Yaounde 1
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity. Trials, record NCT07884058. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884058
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
- NCT number
- NCT07884058
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- University of Yaounde 1
- Conditions
- Obesity & Overweight
- Interventions
- IGOB131, Dextrin
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of IGOB131 on postprandial GLP-1 response (0-180 minutes) | 16 weeks | Postprandial GLP-1 responses will be assessed at baseline and week 16 following ingestion of a standardized test meal. Blood samples will be collected at 0 (fasting), 30, 60, 90, 120, 150, and 180 minutes post-meal. |
| Primary | Effect of IGOB131 on fasting plasma GLP-1 concentrations | 16 weeks | Blood samples will be collected at 0 (fasting), 30, 60, 90, 120, 150, and 180 minutes post-meal. Plasma GLP-1 concentrations will be measured using a validated enzyme-linked immunosorbent assay (ELISA). |
| Primary | Effect of IGOB131 on DPP-4 enzymatic activity | 16 weeks | Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). DPP-4 activity will be determined using a colorimetric assay based on enzymatic cleavage of a specific substrate. |
| Secondary | Effect of IGOB131 on fasting blood glucose | 16 weeks | Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). Fasting glucose will be measured using the glucose oxidase method. |
| Secondary | Effect of IGOB131 on fasting insulin | 16 weeks | Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). Fasting insulin concentrations will be measured by immunoassay. |
| Secondary | Effect of IGOB131 on glycated hemoglobin (HbA1c) | 16 weeks | Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). HbA1c will be measured by high-performance liquid chromatography (HPLC) |
| Secondary | Effect of IGOB131 on homeostatic model assessment for insulin resistance (HOMA-IR) | 16 weeks | Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). HOMA-IR will be calculated using the formula: HOMA-IR = (fasting insulin \[µIU/mL\] × fasting glucose \[mg/dL\]) / 405 |
| Secondary | Effect of IGOB131 on TNF-α | 16 weeks | Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). TNF-α will be quantified using high-sensitivity ELISA kits according to the manufacturer's protocols. |
| Secondary | Effect of IGOB131 on IL-6 | 16 weeks | Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). IL-6 will be quantified using high-sensitivity ELISA kits according to the manufacturer's protocols. |
| Secondary | Effect of IGOB131 on body weight | 16 weeks | Body weight will be measured using a calibrated digital scale with participants wearing light clothing and no shoes. Measurements will be performed in duplicate and averaged. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884058
GET https://conductscience.org/api/trials/v1/NCT07884058/registered